Amendments to the claims

Listing of claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A compound of formula (I):

$$\begin{array}{c|c}
 & A - N & B \\
 & M_1 & W_4 \\
 & W_2 & W_3
\end{array}$$

$$\begin{array}{c|c}
 & Z_1 & Z_5 \\
 & Z_2 & Z_3 & N & Z_4
\end{array}$$
(I)

wherein:

one of Z_1 , Z_2 , Z_3 , Z_4 and Z_5 is N, one is CR^{1a} and the remainder are CH, or one or two of Z_1 , Z_2 , Z_3 , Z_4 and Z_5 are independently CR^{1a} and the remainder are CH;

R¹ and R^{1a} are independently hydrogen; hydroxy; (C_{1-6}) alkoxy unsubstituted or substituted by (C_{1-6}) alkoxy, amino, piperidyl, guanidino or amidino any of which is optionally N-substituted by one or two (C_{1-6}) alkyl, acyl or (C_{1-6}) alkylsulphonyl groups, CONH₂, hydroxy, (C_{1-6}) alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C_{1-6}) alkylsulphonyloxy; (C_{1-6}) alkoxy-substituted (C_{1-6}) alkyl; halogen; (C_{1-6}) alkyl; (C_{1-6}) alkylthio; trifluoromethyl; trifluoromethoxy; nitro; cyano; azido; acyl; acyloxy; acylthio; (C_{1-6}) alkylsulphonyl; (C_{1-6}) alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C_{1-6}) alkyl, acyl or (C_{1-6}) alkylsulphonyl groups; provided that when Z_1 , Z_2 , Z_3 , Z_4 and Z_5 are CR^{1a} or CH, then R^1 is not hydrogen;

W₁, W₂, W₃ and W₄ are each independently selected from N or CR³;

each ${\sf R}^3$ is independently selected from:

hydrogen; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; azido; acyl; acyloxy; acylthio; amino, mono- and di- (C_{1-6}) alkylamino; and substituted and unsubstituted (C_{1-6})alkoxy, (C_{1-6})alkyl, (C_{3-7})cycloalkyl, aminocarbonyl, (C_{1-6})alkylthio, (C_{1-6})alkylsulphonyl, and (C_{1-6})alkylsulphoxide;

A is (CRR)n;

B is $(CRR)_m$, C=O, or SO_2 :

n is 1 or 2;

m is 1 or 2;

provided that when n is 1, m is 2; when n is 2, m is 1; and when B is C=O or SO₂ then n is 2;

each R is independently selected from

hydrogen; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; azido; acyl; acyloxy; acylthio; amino, mono- and di- (C_{1-6}) alkylamino; and substituted and unsubstituted (C_{1-6})alkoxy, (C_{1-6})alkyl, (C_{3-7})cycloalkyl, aminocarbonyl, (C_{1-6})alkylthio, (C_{1-6})alkylsulphonyl, and (C_{1-6})alkylsulphoxide;

R² is a group:

$$R^4$$
 S
 R^4
 S
 R^5

substituted or unsubstituted bicyclic heterocyclic ring system of formula (A):

$$\begin{array}{c|c} X^1 & X^2 & X^3 & \\ \hline & (a) & (b) & \\ Y^1 & X^4 & Y^2 & \\ \hline & & & & & \\ \end{array}$$

containing up to four heteroatoms in each ring in which

ring (a) is substituted or unsubstituted pyridine and ring (b) is substituted or unsubstituted non-aromatic;

X¹-is-C;

X² is N:

X³ and X⁴ are C;

Y¹ is a 2 atom linker group each atom of which is independently selected from CR⁴;

Y² is a 4 atom linker group having S bonded to X⁴ and NHCO bonded via N to X³ in which the other atom is CR⁴R⁵; and

each R^4 and R^5 is independently selected from: hydrogen; (C_{1-4}) alkylthio; halo; carboxy(C_{1-4})alkyl; halo(C_{1-4})alkoxy; halo(C_{1-4})alkyl; (C_{1-4})alkyl; (C_{1-4})alkyl; halo(C_{1-4})alkoxycarbonyl; formyl; (C_{1-4})alkylcarbonyl; (C_{2-4})alkenyloxycarbonyl; (C_{2-4})alkenyloxycarbonyl; (C_{1-4})alkylcarbonyloxy; (C_{1-4})alkoxycarbonyl(C_{1-4})alkyl; hydroxy; hydroxy(C_{1-4})alkyl; mercapto(C_{1-4})alkyl; (C_{1-4})alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl optionally substituted by (C_{1-4})alkoxycarbonyl, (C_{1-4})alkylcarbonyl, (C_{2-4})alkenyloxycarbonyl, (C_{2-4})alkenylcarbonyl, (C_{1-4})alkyl or (C_{2-4})alkenyl and optionally further substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl; (C_{2-6})alkenyl; (C_{1-4})alkylsulphonyl; (C_{2-4})alkenylsulphonyl; aminosulphonyl wherein the amino group is optionally mono- or di-substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl; aryl; aryl(C_{1-4})alkyl;

wherein the term acyl means a formyl or a (C₁₋₆)alkylcarbonyl group;

and aryl(C₁₋₄)alkoxy; or R⁴ and R⁵ may together represent oxo;

or a pharmaceutically acceptable salt thereof.

2. (Previously presented) A compound according to claim 1 wherein Z_5 is CH or N, Z_3 is CH or CF and Z_1 , Z_2 and Z_4 are each CH.

- 3. (Original) A compound according to claim 1 wherein R^1 is methoxy and R^{1a} is H or when Z_3 is CR^{1a} it may be C-F.
- 4. (Previously presented) A compound according to claim 1 wherein W_1 - W_4 are independently CR^3 .
- 5. (Original) A compound according to claim 1 wherein \mathbb{R}^3 is independently selected from hydrogen, substituted and unsubstituted (\mathbb{C}_{1-6})alkoxy, and \mathbb{NH}_2 .
- 6. (Original) A compound according to claim 1 wherein R is independently selected from hydrogen, substituted and unsubstituted (C_{1-6})alkyl, CONH₂, COOH, hydroxy, halogen, and substituted and unsubstituted (C_{1-6})alkoxy.
- 7. (Canceled)
- 8. (Previously presented) A compound according to claim 1 wherein R^2 is 4H-pyrido[3,2-b][1,4]thiazin-3-one-6-yl.
- 9. (Previously presented) A compound according to claim 1 which is:
- 6-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;
- $6-({2-[4-(6,8-difluoroquinolin-4-yl)phenyl]ethylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;$
- 6-({2-[4-(8-Fluoro-6-methoxyquinolin-4-yl)phenyl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;
- 6-({2-[6-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-3-yl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

6-({2-[5-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-2-yl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

N-(2-{6-[6-(methyloxy)-1,5-naphthyridin-4-yl]-3-pyridinyl}ethyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxamide; or

N-(2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxamide; or a pharmaceutically acceptable salt thereof.

10. (Original) A pharmaceutical composition comprising a compound according to claim1 and a pharmaceutically acceptable carrier.

11-13. (Canceled)

- 14. (Previously presented) A compound according to claim 1 wherein Z_1 is N, Z_3 is CH or CF and Z_2 , Z_4 and Z_5 are each CH.
- 15. (Previously presented) A compound according to claim 1 wherein W_1 , W_3 and W_4 are N and W_2 is CR^3 .
- 16. (Previously presented) A compound according to claim 1 wherein W_2 is N and W_1 , W_3 and W_4 are independently CR³.
- 17. (Previously presented) A compound according to claim 1 wherein W_3 is N and W_1 , W_2 and W_4 are independently CR³.
- 18. (Previously presented) A compound according to claim 1 wherein W_4 is N and W_1 W_3 are independently CR 3 .
- 19. (Currently amended) A compound according to claim 1 wherein R⁴ is independently hydrogen, fluorine or nitro and R⁵ is hydrogen.

20. (Previously presented) A compound according to claim 1 wherein R is hydrogen.

21. (Previously presented) A compound according to claim 1 wherein R³ is hydrogen.